May 6, 2025 01:30AM
Apr 24, 2024 01:00AM
Oct 23, 2023 01:00AM
Jul 21, 2023 08:52AM
Jul 21, 2023 07:52AM
Apr 27, 2023 01:00AM
Mar 2, 2023 02:13PM Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio
Feb 22, 2023 01:00AM
Feb 15, 2023 01:00AM
Feb 9, 2023 01:00AM
Jan 9, 2023 04:52AM
Jan 9, 2023 01:00AM
Oct 27, 2022 12:57AM
Aug 12, 2022 11:35AM Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology
Aug 5, 2022 01:00AM
Jul 28, 2022 12:57AM
Jun 29, 2022 01:00AM
Jun 27, 2022 01:01AM
Jun 27, 2022 01:00AM
May 24, 2022 01:00AM
Feb 11, 2022 01:00AM Ipsen Presents Strong Full-Year 2021 Results and Enters Into Exclusive Negotiations to Divest Its Consumer Healthcare Business
Jan 24, 2022 01:00AM
Aug 13, 2021 01:00AM
Jul 29, 2021 01:00AM
May 28, 2021 01:49PM
May 27, 2021 01:00AM
Apr 22, 2021 01:00AM
Apr 1, 2021 04:15PM Fusion Pharmaceuticals Announces Closing of Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen
Mar 2, 2021 07:39AM
Mar 2, 2021 07:30AM
Feb 11, 2021 12:58AM
Sep 14, 2020 01:00AM
Sep 10, 2020 01:00AM
Aug 25, 2020 01:00AM
Jul 30, 2020 01:00AM Ipsen Presents Its Half Year 2020 Results and Reinstates Guidance for Full Year 2020
Jun 8, 2020 01:00AM
May 29, 2020 01:05AM
May 29, 2020 01:00AM
May 4, 2020 01:00AM
Mar 26, 2020 02:00AM
Feb 13, 2020 01:00AM
Jan 24, 2020 01:00AM Ipsen’s palovarotene clinical program in fibrodysplasia ossificans progressiva reaches prespecified interim analysis futility criteria
Oct 16, 2019 01:00AM
Sep 26, 2019 01:00AM
Jul 25, 2019 01:00AM
May 28, 2019 01:30AM
May 24, 2019 01:00AM
May 14, 2019 01:00AM
Apr 24, 2019 01:00AM Ipsen Reports Strong Double-Digit Sales Growth in First Quarter 2019 and Confirms Full Year 2019 Financial Targets
Apr 18, 2019 01:00AM

1,155,258 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All